Vestibular schwannomas: Treatment with bevacizumab

Daniel M.S. Raper, Ricardo J Komotar

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Currently there are no established medical treatments for vestibular schwannoma. Surgery may result in vestibular nerve damage and hearing loss, while radiotherapy can lead to cranial nerve neuropathy and increase the risk of secondary malignancy. Due to its effect on the VEGF pathway, which has been shown to be dysregulated in vestibular schwannomas, bevacizumab has been investigated as a potentially efficacious medical therapy for schwannomas that are unsuitable for surgical resection. Though the place of this treatment in the paradigm of vestibular schwannoma therapy remains to be fully understood, it represents a promising advance for a complex disease for which few satisfactory options currently exist.

Original languageEnglish (US)
Title of host publicationTumors of the Central Nervous System, Volume 7
Subtitle of host publicationMeningiomas and Schwannomas
PublisherSpringer Netherlands
Pages335-339
Number of pages5
ISBN (Electronic)9789400728943
ISBN (Print)9789400728936
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Vestibular schwannomas: Treatment with bevacizumab'. Together they form a unique fingerprint.

  • Cite this

    Raper, D. M. S., & Komotar, R. J. (2012). Vestibular schwannomas: Treatment with bevacizumab. In Tumors of the Central Nervous System, Volume 7: Meningiomas and Schwannomas (pp. 335-339). Springer Netherlands. https://doi.org/10.1007/978-94-007-2894-3_36